List of Zuplenz drug patents

Zuplenz is owned by Aquestive.

Zuplenz contains Ondansetron.

Zuplenz has a total of 2 drug patents out of which 0 drug patents have expired.

Zuplenz was authorised for market use on 02 July, 2010.

Zuplenz is available in film;oral dosage forms.

The generics of Zuplenz are possible to be released after 13 July, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8580830 AQUESTIVE Non-mucoadhesive film dosage forms
Nov, 2029

(6 years from now)

US9095577 AQUESTIVE Stabilized amine-containing actives in oral film compositions
Jul, 2030

(7 years from now)

Drugs and Companies using ONDANSETRON ingredient

Market Authorisation Date: 02 July, 2010

Treatment: NA

Dosage: FILM;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic